A Phase I/IIa, First Time in Human, Open-label Dose-escalation Study of GSK2636771 in Subjects With Advanced Solid Tumors With PTEN Deficiency
Latest Information Update: 15 Jul 2022
At a glance
- Drugs GSK 2636771 (Primary) ; Pembrolizumab (Primary)
- Indications Advanced breast cancer; Colorectal cancer; Endometrial cancer; Gastric cancer; Glioblastoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 07 Jun 2022 Results from a cohort of patients with metastatic castration-resistant prostate cancer and PTEN loss presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 21 Sep 2021 Results of an analysis assessing the safely, tolerability and clinical activity of pembrolizumab in combination with GSK2636771 will be in patients with PTEN loss presented at the 46th European Society for Medical Oncology Congress
- 19 Nov 2017 According to The Institute of Cancer Research media release, results from this trial have been published in Clinical Cancer Research.